Sumitomo Mitsui Trust Group Inc. Has $67.46 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui Trust Group Inc. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 286,703 shares of the biopharmaceutical company's stock after purchasing an additional 8,462 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.22% of Alnylam Pharmaceuticals worth $67,464,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Huntington National Bank boosted its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 45 shares during the period. SYM FINANCIAL Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 55 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company's stock worth $157,000 after buying an additional 57 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock worth $1,532,000 after acquiring an additional 58 shares during the period. Finally, Harbor Capital Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock valued at $624,000 after purchasing an additional 63 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Activity

In other news, CMO Pushkal Garg sold 1,682 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares of the company's stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,964 shares of company stock worth $20,622,925. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $1.07 on Thursday, reaching $264.89. The company had a trading volume of 769,150 shares, compared to its average volume of 680,181. The stock has a market capitalization of $34.17 billion, a PE ratio of -101.10 and a beta of 0.35. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business's 50-day moving average is $254.03 and its 200 day moving average is $263.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the subject of several research reports. StockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Piper Sandler reissued an "overweight" rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Chardan Capital reaffirmed a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a "sector outperform" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.